Suppr超能文献

表观遗传学推动癌症治疗中的个体化纳米医学。

Epigenetics advancing personalized nanomedicine in cancer therapy.

机构信息

The Hormel Institute, University of Minnesota, Austin, MN 55912, USA.

出版信息

Adv Drug Deliv Rev. 2012 Oct;64(13):1532-43. doi: 10.1016/j.addr.2012.08.004. Epub 2012 Aug 19.

Abstract

Personalized medicine aims to deliver the right drug to a right patient at the right time. It offers unique opportunities to integrate new technologies and concepts to disease prognosis, diagnosis and therapeutics. While selective personalized therapies are conceptually impressive, the majority of cancer therapies have dismal outcome. Such therapeutic failure could result from no response, drug resistance, disease relapse or severe side effect from improper drug delivery. Nanomedicine, the application of nanotechnology in medicine, has a potential to advance the identification of diagnostic and prognostic biomarkers and the delivery of right drug to disease sites. Epigenetic aberrations dynamically contribute to cancer pathogenesis. Given the individualized traits of epigenetic biomarkers, epigenetic considerations would significantly refine personalized nanomedicine. This review aims to dissect the interface of personalized medicine with nanomedicine and epigenetics. I will outline the progress and highlight challenges and areas that can be further explored perfecting the personalized health care.

摘要

个性化医疗旨在在正确的时间将正确的药物提供给正确的患者。它为整合新技术和新概念以进行疾病预后、诊断和治疗提供了独特的机会。虽然选择性的个性化治疗在概念上令人印象深刻,但大多数癌症治疗的效果并不理想。这种治疗失败可能是由于没有反应、耐药性、疾病复发或由于药物输送不当而产生严重的副作用。纳米医学是纳米技术在医学中的应用,它有可能促进诊断和预后生物标志物的识别以及将正确的药物输送到疾病部位。表观遗传学异常动态地促进癌症的发病机制。鉴于表观遗传生物标志物的个体化特征,对表观遗传学的考虑将显著完善个性化纳米医学。本综述旨在剖析个性化医学与纳米医学和表观遗传学的接口。我将概述进展,并强调可以进一步探索的挑战和领域,以完善个性化医疗保健。

相似文献

1
Epigenetics advancing personalized nanomedicine in cancer therapy.
Adv Drug Deliv Rev. 2012 Oct;64(13):1532-43. doi: 10.1016/j.addr.2012.08.004. Epub 2012 Aug 19.
2
Omics-based nanomedicine: the future of personalized oncology.
Cancer Lett. 2014 Sep 28;352(1):126-36. doi: 10.1016/j.canlet.2013.07.029. Epub 2013 Aug 11.
3
Toward personalized cancer nanomedicine - past, present, and future.
Integr Biol (Camb). 2013 Jan;5(1):48-65. doi: 10.1039/c2ib20104f.
4
Epigenetics of Early Cardiometabolic Disease: Mechanisms and Precision Medicine.
Circ Res. 2023 Jun 9;132(12):1648-1662. doi: 10.1161/CIRCRESAHA.123.322135. Epub 2023 Jun 8.
5
Biologics, theranostics, and personalized medicine in drug delivery systems.
Pharmacol Res. 2024 Mar;201:107086. doi: 10.1016/j.phrs.2024.107086. Epub 2024 Jan 29.
6
Nanotheranostics for personalized medicine.
Expert Rev Mol Diagn. 2013 Apr;13(3):257-69. doi: 10.1586/erm.13.15.
7
Promises of Nanotherapeutics in Obesity.
Trends Endocrinol Metab. 2019 Jun;30(6):369-383. doi: 10.1016/j.tem.2019.04.004. Epub 2019 May 21.
8
Synthetic Lethality: From Research to Precision Cancer Nanomedicine.
Curr Cancer Drug Targets. 2018;18(4):337-346. doi: 10.2174/1568009617666170630141931.
9
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Drug Resist Updat. 2017 Mar;31:15-30. doi: 10.1016/j.drup.2017.05.002. Epub 2017 May 21.
10
Advanced nanomedicine and cancer: Challenges and opportunities in clinical translation.
Int J Pharm. 2021 Apr 15;599:120438. doi: 10.1016/j.ijpharm.2021.120438. Epub 2021 Mar 2.

引用本文的文献

1
DNA Methylation in Cancer: Epigenetic View of Dietary and Lifestyle Factors.
Epigenet Insights. 2023 Sep 15;16:25168657231199893. doi: 10.1177/25168657231199893. eCollection 2023.
2
Gene Therapy Using Efficient Direct Lineage Reprogramming Technology for Neurological Diseases.
Nanomaterials (Basel). 2023 May 19;13(10):1680. doi: 10.3390/nano13101680.
4
A Review on Drug Delivery System for Tumor Therapy.
Front Pharmacol. 2021 Oct 4;12:735446. doi: 10.3389/fphar.2021.735446. eCollection 2021.
5
Investigating the Application of Liposomes as Drug Delivery Systems for the Diagnosis and Treatment of Cancer.
Int J Biomater. 2021 Sep 1;2021:3041969. doi: 10.1155/2021/3041969. eCollection 2021.
6
An Assessment on Ethanol-Blended Gasoline/Diesel Fuels on Cancer Risk and Mortality.
Int J Environ Res Public Health. 2021 Jun 28;18(13):6930. doi: 10.3390/ijerph18136930.
7
Nanomaterials for Protein Delivery in Anticancer Applications.
Pharmaceutics. 2021 Jan 25;13(2):155. doi: 10.3390/pharmaceutics13020155.
8
Epigenetics in cancer therapy and nanomedicine.
Clin Epigenetics. 2019 May 16;11(1):81. doi: 10.1186/s13148-019-0675-4.

本文引用的文献

1
My microbiome and me.
Science. 2012 Jun 8;336(6086):1248-50. doi: 10.1126/science.336.6086.1248. Epub 2012 Jun 6.
2
Is it time for a metagenomic basis of therapeutics?
Science. 2012 Jun 8;336(6086):1253-5. doi: 10.1126/science.1224396. Epub 2012 Jun 6.
3
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
Blood. 2012 Jun 21;119(25):6025-31. doi: 10.1182/blood-2012-03-413898. Epub 2012 May 7.
4
The microcosmos of cancer.
Nature. 2012 Feb 15;482(7385):347-55. doi: 10.1038/nature10888.
5
Epigenetic mechanisms in cartilage and osteoarthritis: DNA methylation, histone modifications and microRNAs.
Osteoarthritis Cartilage. 2012 May;20(5):339-349. doi: 10.1016/j.joca.2011.12.012. Epub 2012 Jan 10.
6
Incidence of acute myeloid leukemia after breast cancer.
Mediterr J Hematol Infect Dis. 2011;3(1):e2011069. doi: 10.4084/MJHID.2011.069. Epub 2011 Dec 22.
7
Treating metastatic cancer with nanotechnology.
Nat Rev Cancer. 2011 Dec 23;12(1):39-50. doi: 10.1038/nrc3180.
8
Epigenomic and microRNA-mediated regulation in cartilage development, homeostasis, and osteoarthritis.
Trends Mol Med. 2012 Feb;18(2):109-18. doi: 10.1016/j.molmed.2011.11.005. Epub 2011 Dec 17.
9
Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies.
BMC Cancer. 2011 Nov 30;11:500. doi: 10.1186/1471-2407-11-500.
10
Epigenetic biomarker development.
Epigenomics. 2009 Oct;1(1):99-110. doi: 10.2217/epi.09.6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验